차 례 ▢ 평가배경 초음파유도 고강도초음파집속술(Ultrasound guided-High Intensity Focused Ultrasound, USg-HIFU)은 B-mode 초음파 유도 하에 체외 초음파를 이용하여 고형종양의 응고괴사를 유도하는 최소(비)침습적 치료법이다. 본 기술은 간암에 한해서 2008년 신의료기술로 인정되어 비급여로 등재되었다.
▢ 위원회 운영 총 6인으로 구성된 소위원회는 2019년 4월부터 2019년 8월까지 약 5개월에 걸쳐 총 4회의 소위원회를 운영하며 문헌적 근거에 따라 해당 시술을 평가하고 검토결과를 제출하였다.
▢ 평가 목적 및 방법 간암대상 초음파유도 고강도초음파집속술의 안전성 및 효과성의 근거를 평가하기 위하여 체계적 문헌고찰을 실시하였다. 자세한 연구방법은 아래와 같고, 모든 평가방법은 연구목적을 고려하여 “간암의 초음파유도 고강도초음파집속술에 대한 안전성 및 유효성 평가 소위원회(이하 ‘소위원회’라 한다)”의 심의를 거쳐 확정하였다. 체계적 문헌고찰은 위의 핵심질문을 토대로 국외 3개, 국내 5개 데이터베이스에서 검색하였으며, 문헌선정 및 배제기준에 따라 두 명의 검토자가 독립적으로 선별하고 선택하였다. 문헌의 비뚤림 위험 평가는 Risk of Bias 또는 RoBANS를 사용하여 두 명의 검토자가 독립적으로 수행하고 의견합의를 이루었다. 자료추출은 미리 정해놓은 자료추출 양식을 활용하여 두 명의 검토자가 독립적으로 수행하였으며, 의견 불일치가 있을 경우 함께 논의하여 합의하였다. 자료분석은 정량적 분석(quantitative analysis)이 가능하지 않아 정성적(qualitative review) 분석을 적용하였다.
-----------------------------------중 략-----------------------------------
Ultrasound guided-high intensity focused
ultrasound (USg-HIFU) is a minimally (non) invasive treatment method that uses B-mode
ultrasound guided extracorporeal ultrasound to induce coagulation necrosis of
solid tumors. This technique was recognized as a new health technology for
liver cancer only in 2010 and has been registered as a non-coverage item.
A subcommittee consisting of six
members held a total of four subcommittee sessions over a 5-month period
between April and August 2019 to submit the results of assessment and review of
this procedure based on literary evidence.
▢ Assessment objectives and methods
A systematic literature review was
performed to assess the evidence for the safety and effectiveness of USg-HIFU
for liver cancer. Detailed study methods were as follows and all assessment
methods were established through review and approval by the “Subcommittee for
the Assessment of USg-HIFU Safety and Effectiveness for Liver Cancer” (hereinafter
the Subcommittee) with consideration for the study objectives.
For
systematic literature review, five Korean and three foreign databases were searched
based on the key question above. Two reviewers independently screened and
selected the articles according to the selection and exclusion criteria. Risk
of bias assessment was performed independently by two reviewers using RoBANS to
reach an agreement. Data were extracted independently by two reviewers using
pre-determined format. If there was a disagreement between the reviewers, such
cases were discussed with a third party to reach an agreement. For data
analysis, since quantitative analysis was possible, qualitative review was
applied.
Table. Details of PICO-TS
|
|
|
Primary liver cancer
Metastatic liver cancer
|
|
Ultrasound guided-high intensity focused
ultrasound (USg-HIFU)
|
|
Surgery
Non-invasive procedure
|
|
- Safety
∙ Fever,
(secondary) infection, abscess, skin burn, subcutaneous fat edema, abdominal
pain, ascites, diarrhea, gastrointestinal perforation, pancreatic duct
stenosis, peripheral organ damage, tissue and vascular coagulation necrosis,
tumor bleed, large vessel rupture, postoperative embolism, tissue destruction
by cavitation, adverse events, etc.
- Effectiveness
∙ AFP level
∙ Complete necrosis rate concept indicators
including complete response (CR)
∙ Partial response (PR)
∙ Stable disease (SD)
∙ Progressive disease (PD)
∙ Survival rate: overall
|
|
|
|
Randomized controlled trials (RCTs),
non-randomized studies (cohort, cross-sectional, and pre-post comparison
studies), case studies, and case reports
|
|
2007 ~ Search date (May 3, 2019)
|
A total of 24 articles were used in the
assessment, which included 18 articles selected from searching domestic/foreign
databases according to predetermined protocol and six articles used to at the
time of new health technology assessment. Safety and effectiveness assessment
results were as follows:
Based on articles reporting that there
are serious postoperative complications or adverse events after USg-HIFU for
liver cancer, the Subcommittee determined that it is necessary to consider the
condition of the patient during the procedure. Moreover, because some articles
reported third degree burn and rib fracture and the area where high intensity ultrasound
is focused and the experience of the operator are associated with occurrence of
complications, it was determined that preventing occurrence of complication
through enough experience and training is important from a safety aspect.
From an effectiveness aspect, most
articles reported that complete/partial response rate and overall survival rate
were higher and stable/progressive disease rate was lower in the USg-HIFU group
than the comparator group. Accordingly, it was determined that USg-HIFU has a
therapeutic effect as curative and palliative treatment modality, and thus, the
need for this was agreed in subcommitte. However, there was only one RCT in the
past 10 years and most relevant studies were case studies or case reports,
while comparison studies reported that USg-HIFU is valuable when combined with
other procedures. Therefore, it was determined that additional studies are
needed to confirm the effects of USg-HIFU as a standalone therapy.
The Health
Technology Reassessment Committee reviewed and determined that the findings of
the Subcommittee on “USg-HIFU for liver cancer” are valid (October 11, 2019).
Ⅰ. 서론 1 1. 평가배경 1 1.1. 평가대상 의료기술 2 1.2. 질병 및 현존하는 의료기술 6 1.3. 국내외 급여현황 11
Ⅱ. 평가방법 13 1. 체계적 문헌고찰 13 1.1. 개요 13 1.2. PICO-TS 13 1.3. 문헌검색 15 1.4. 문헌선정 16 1.5. 비뚤림 위험 평가 16 1.6. 자료추출 17 1.7. 근거수준 평가 18 2. 위원회 운영 18
Ⅲ.평가결과 19 1. 문헌선정 결과 19 1.1. 선정 문헌 특성 20 1.2. 비뚤림 위험 평가결과 22 2. 분석결과 24 2.1. 안전성 24 2.2. 유효성 32 3. GRADE 근거 평가 45
Ⅳ. 요약 및 결론 57 1. 평가 요약 57 2. 결론 58 2.1. 간암 초음파유도 HIFU의 안전성 58 2.2. 간암 초음파유도 HIFU의 유효성 59 2.3. 간암 초음파유도 HIFU의 안전성 및 유효성 62
Ⅴ. 참고문헌 63
Ⅵ. 부록 67 1. 소위원회 67 2. 문헌 검색 전략 68 3. 최종 선택 문헌 71 4. 배제문헌 목록 73 5. 신의료기술평가보고서(2008) 평가 결과 77
|